Regulatory 2024-02-09 | Q4 and Full Year Report 2023: Strengthened Financial Position Ahead of SPARKLE Phase 3 Study Headline Results in May PDF Report Presentation Webcast
Regulatory 2023-02-10 | QUARTERLY REPORT Q4 2022: Orviglance phase 3 study, SPARKLE, expected to be completed in Q1 2023. PDF Report Presentation Webcast
Regulatory 2022-02-10 | Quarterly Report Q4 2021: Strong data for Orviglance vs. a gadolinium contrast agent PDF Report Presentation Webcast
Regulatory 2021-02-16 | Quarterly Report Q4 2020: Mangoral shows high diagnostic value in new study PDF Report Presentation Webcast
Regulatory 2020-02-14 | 2019 year-end financial report: Sites opened for recruitment to the pivotal Phase III study SPARKLE PDF Report Presentation Webcast
Regulatory 2019-08-22 | Phase III study of Mangoral to start in H2-2019 PDF Report Presentation Webcast
